Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1358.5, up 1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.7% on the day, quoting at 23097.15. The Sensex is at 74679.77, up 0.71%. Dr Reddys Laboratories Ltd has gained around 12.63% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 3.45% in last one month and is currently quoting at 26710.8, up 1.9% on the day. The volume in the stock stood at 9.74 lakh shares today, compared to the daily average of 23.67 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 1360.8, up 1.01% on the day. Dr Reddys Laboratories Ltd is up 13.44% in last one year as compared to a 10.21% slide in NIFTY and a 22.74% slide in the Nifty Pharma index.
The PE of the stock is 114.99 based on TTM earnings ending September 26.
Net profit attributable to equity shareholders of the parent company fell 35.6% year on year to Rs 925 crore from Rs 1,437.2 crore in Q2 FY26. Sequentially, net profit rose 108.6% from Rs 443.5 crore in Q1 FY27.
Gross profit declined 6.1% year on year to Rs 4,520.4 crore from Rs 4,814 crore. Gross margin narrowed to 52.1% from 54.7% a year earlier, but improved from 46.5% in Q1 FY27.
Profit before tax declined 33.1% year on year to Rs 1,227.7 crore from Rs 1,835 crore in Q2 FY26. It rose 122.2% quarter on quarter from Rs 552.6 crore in Q1 FY27.
The company reported EBITDA of Rs 1,783 crore, with a margin of 20.6%, and a net cash surplus of Rs 2,502 crore. EBITDA declined 24% year on year and increased 77% quarter on quarter. Q1 FY27 was impacted by a Rs 240 crore provision for inventory and other costs related to the semaglutide API issue.
Selling, general and administrative expenses increased 6.2% year on year to Rs 2,807.5 crore, while research and development expenses declined 15.6% to Rs 523.5 crore.
The global generics business recorded revenue of Rs 7,792.7 crore, down 0.7% year on year but up 8.2% quarter on quarter. North America revenue fell 23.2% year on year to Rs 2,489 crore. Emerging markets revenue rose 24.4% to Rs 2,059.5 crore, while India revenue increased 17.3% to Rs 1,850.8 crore. Europe revenue grew 1.3% to Rs 1,393.5 crore. Revenue from pharmaceutical services and active ingredients declined 12.1% to Rs 831 crore.
The company said lower lenalidomide sales in North America primarily affected quarterly revenue. Excluding lenalidomide sales in North America, its underlying base business continued to deliver double-digit growth across businesses, except Europe and active pharmaceutical ingredients, supported by favourable currency movements.
“We continued to improve the overall health of our business, delivering double-digit base business growth and EBITDA margins of over 20% during the quarter,” said G V Prasad, co-chairman and managing director. He added that the company remained focused on strengthening its core businesses, enhancing productivity and investing in strategic growth platforms.
Dr. Reddy's Laboratories is a Hyderabad-based global pharmaceutical company offering APIs, generics, branded generics, biosimilars and OTC products. Its key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Major markets include the US, India, Russia and CIS countries, China, Brazil and Europe.
Dr Reddy's Laboratories shares jumped 5.88% to Rs 1,296.50 on the BSE.
Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1243, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 22670.45. The Sensex is at 72404.26, down 0.5%. Dr Reddys Laboratories Ltd has gained around 7.67% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 1.12% in last one month and is currently quoting at 26761.65, up 0.45% on the day. The volume in the stock stood at 34.38 lakh shares today, compared to the daily average of 14.98 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1241.9, up 1.45% on the day. Dr Reddys Laboratories Ltd is up 1.58% in last one year as compared to a 7.89% slide in NIFTY and a 25.3% slide in the Nifty Pharma index.
The PE of the stock is 153.77 based on TTM earnings ending June 26.
Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23448.85. The Sensex is at 74923.95, up 0.53%. Dr Reddys Laboratories Ltd has risen around 1.93% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 2.32% in last one month and is currently quoting at 26909.6, up 0.15% on the day. The volume in the stock stood at 5.57 lakh shares today, compared to the daily average of 14.49 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1213.1, up 0.51% on the day. Dr Reddys Laboratories Ltd is down 6.56% in last one year as compared to a 6.42% drop in NIFTY and a 21.5% drop in the Nifty Pharma index.
The PE of the stock is 152.45 based on TTM earnings ending June 26.
Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1208.6, up 1.99% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74819.64, up 0.71%. Dr Reddys Laboratories Ltd has added around 1.56% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 8.06 lakh shares today, compared to the daily average of 13.35 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1205.2, up 1.8% on the day. Dr Reddys Laboratories Ltd is down 7.13% in last one year as compared to a 7.1% fall in NIFTY and a 20.91% fall in the Nifty Pharma index.
The PE of the stock is 147.31 based on TTM earnings ending June 26.
The collaboration follows the approval of QDENGA's marketing authorization by India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India's first approved dengue vaccine, the approval marks an important milestone in the country's efforts to strengthen dengue prevention and management.